CL-108
Moderate to Severe Acute Pain with prevention/reduction of Opioid-Induced Nausea and Vomiting (OINV)
NDA ResubmittedActive
Key Facts
Indication
Moderate to Severe Acute Pain with prevention/reduction of Opioid-Induced Nausea and Vomiting (OINV)
Phase
NDA Resubmitted
Status
Active
Company
About Charleston Laboratories
Charleston Laboratories is a private, clinical-stage biotech company pioneering a novel approach to acute pain management by co-formulating analgesics with antiemetics to mitigate debilitating side effects. The company's lead asset, CL-108, has completed Phase 3 studies and has resubmitted an NDA, positioning it as a near-term potential commercial product. With a focused pipeline built on its proprietary technology platform, Charleston aims to shift the treatment paradigm in acute pain care by improving patient tolerability and recovery.
View full company profile